Factor Xa Inhibitors

Factor Xa Inhibitor

Pulmonary Embolism

Venous Thrombosis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>Rivaroxaban, a factor Xa (FXa) inhibitor, is the active ingredient in XARELTO ® Tablets and XARELTO ® for oral suspension with the chemical name 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide. The molecular formula of rivaroxaban is C 19H 18ClN 3O 5S and the molecular weight is 435.89. The structural formula is: <div class="Figure"><img alt="Chemical Structure" src="xarelto-02.jpg"/></div>Rivaroxaban is a pure ( S)-enantiomer. It is an odorless, non-hygroscopic, white to yellowish powder. Rivaroxaban is only slightly soluble in organic solvents (e.g., acetone, polyethylene glycol 400) and is practically insoluble in water and aqueous media. Each XARELTO tablet contains 2.5 mg, 10 mg, 15 mg, or 20 mg of rivaroxaban. The inactive ingredients of XARELTO are: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. Additionally, the proprietary film coating mixture used for XARELTO 2.5 mg is Opadry ® Light Yellow, containing ferric oxide yellow, hypromellose, polyethylene glycol 3350, and titanium dioxide, and for XARELTO 10 mg tablets is Opadry ® Pink and for XARELTO 15 mg tablets is Opadry ® Red, both containing ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide, and for XARELTO 20 mg tablets is Opadry ® II Dark Red, containing ferric oxide red, polyethylene glycol 3350, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide. XARELTO for oral suspension is supplied as granules in bottles containing 155 mg of rivaroxaban (1 mg of rivaroxaban per mL after reconstitution). The inactive ingredients are: anhydrous citric acid, hypromellose, mannitol, microcrystalline cellulose and carboxymethylcellulose sodium, sodium benzoate, sucralose, sweet and creamy flavor and xanthan gum.</section>

XARELTO

rivaroxaban

rivaroxaban 10 MG Oral Tablet

Xarelto

rivaroxaban 10 MG Oral Tablet [Xarelto]

rivaroxaban 15 MG Oral Tablet

rivaroxaban 15 MG Oral Tablet [Xarelto]

rivaroxaban 20 MG Oral Tablet

rivaroxaban 20 MG Oral Tablet [Xarelto]

rivaroxaban 2.5 MG Oral Tablet

rivaroxaban 2.5 MG Oral Tablet [Xarelto]

rivaroxaban 1 MG/ML Oral Suspension

rivaroxaban 1 MG/ML Oral Suspension [Xarelto]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Online Sample Form 

Formulary Coverage 

Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Appeals Consideration Checklist

Appeals Consideration Checklist - Spanish

Letter of Medical Necessity 

Letter of Formulary Exception

Formulary Exception Considerations Checklist 

Janssen CarePath HCP Portal 

Enroll in Patient Savings Program 

Enroll in Patient Savings Program (Janssen Select - To address coverage gap for commercial & government insurance) 

J & J Patient Assistance Program Eligibility Check 

Other HCP Resources

About Xarelto: All Indications 

About Xarelto: Nonvalvular Atrial Fibrillation

FAQs: Nonvalvular Atrial Fibrillation

Patient Stories: Nonvalvular Atrial Fibrillation

Instructions For Use: Nonvalvular Atrial Fibrillation 

Doctor Discussion Guide: Nonvalvular Atrial Fibrillation

About Xarelto: Peripheral Artery Disease (PAD)

FAQs: Peripheral Artery Disease (PAD)

Doctor Discussion Guide: Peripheral Artery Disease (PAD) 

Instructions For Use: Peripheral Artery Disease (PAD) 

Instructions For Use: Coronary Artery Disease (CAD)

About Xarelto: Coronary Artery Disease (CAD)

FAQs: Coronary Artery Disease (CAD)

Patient Stories: Coronary Artery Disease (CAD)

Doctor Discussion Guide: Coronary Artery Disease (CAD)

About Xarelto: Deep Vein Thrombosis (DVT) 

FAQs: Deep Vein Thrombosis (DVT) 

Patient Stories: Deep Vein Thrombosis (DVT) 

Doctor Discussion Guide: Deep Vein Thrombosis (DVT)

Instructions For Use: Deep Vein Thrombosis (DVT) 

About Xarelto: Pulmonary Embolism (PE)

FAQs: Pulmonary Embolism (PE)

Patient Stories: Pulmonary Embolism (PE)

Doctor Discussion Guide: Pulmonary Embolism (PE) 

Instructions For Use: Pulmonary Embolism (PE) 

About Xarelto: DVT Prophylaxis After Hip/Knee Replacement Surgery

FAQs: DVT Prophylaxis After Hip/Knee Replacement Surgery

Instructions For Use: DVT Prophylaxis After Hip/Knee Replacement Surgery

About Xarelto: DVT/PE Prophylaxis in Non-Surgical Hospitalization

FAQs: DVT/PE Prophylaxis in Non-Surgical Hospitalization

Instructions For Use: DVT/PE Prophylaxis in Non-Surgical Hospitalization 

About Xarelto: Pediatric DVT/PE 

Instructions For Use: Pediatric DVT/PE 

About Xarelto: Pediatric Post Fontan

Instructions For Use: Pediatric Post Fontan